Reshape Lifesciences Stock Current Valuation
| RSLS Stock | USD 0.66 0.04 5.71% |
Valuation analysis of ReShape Lifesciences helps investors to measure ReShape Lifesciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, ReShape Lifesciences' Enterprise Value Over EBITDA is comparatively stable compared to the past year. Enterprise Value Multiple is likely to gain to 0.18 in 2025, despite the fact that Enterprise Value is likely to grow to (3 M). Fundamental drivers impacting ReShape Lifesciences' valuation include:
Fairly Valued
Today
Please note that ReShape Lifesciences' price fluctuation is out of control at this time. Calculation of the real value of ReShape Lifesciences is based on 3 months time horizon. Increasing ReShape Lifesciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the ReShape stock is determined by what a typical buyer is willing to pay for full or partial control of ReShape Lifesciences. Since ReShape Lifesciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ReShape Stock. However, ReShape Lifesciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.66 | Real 0.63 | Target 1.0 | Hype 0.66 | Naive 0.48 |
The intrinsic value of ReShape Lifesciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ReShape Lifesciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ReShape Lifesciences helps investors to forecast how ReShape stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ReShape Lifesciences more accurately as focusing exclusively on ReShape Lifesciences' fundamentals will not take into account other important factors: ReShape Lifesciences Company Current Valuation Analysis
ReShape Lifesciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ReShape Lifesciences Current Valuation | 1.6 M |
Most of ReShape Lifesciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ReShape Lifesciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ReShape Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for ReShape Lifesciences is extremely important. It helps to project a fair market value of ReShape Stock properly, considering its historical fundamentals such as Current Valuation. Since ReShape Lifesciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ReShape Lifesciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ReShape Lifesciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ReShape Lifesciences has a Current Valuation of 1.6 M. This is 99.99% lower than that of the Health Care Equipment & Supplies sector and 99.99% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
ReShape Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ReShape Lifesciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ReShape Lifesciences could also be used in its relative valuation, which is a method of valuing ReShape Lifesciences by comparing valuation metrics of similar companies.ReShape Lifesciences is currently under evaluation in current valuation category among its peers.
ReShape Lifesciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of ReShape Lifesciences from analyzing ReShape Lifesciences' financial statements. These drivers represent accounts that assess ReShape Lifesciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ReShape Lifesciences' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 17.6M | 17.9M | 2.9M | 1.5M | 1.7M | 1.6M | |
| Enterprise Value | 15.1M | (4.6M) | (823.6K) | (2.7M) | (3.1M) | (3.0M) |
ReShape Fundamentals
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.63 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (1.05) % | ||||
| Current Valuation | 1.6 M | ||||
| Shares Outstanding | 712.68 K | ||||
| Shares Owned By Insiders | 5.57 % | ||||
| Shares Owned By Institutions | 1.83 % | ||||
| Number Of Shares Shorted | 82.81 K | ||||
| Price To Book | 1.44 X | ||||
| Price To Sales | 0.27 X | ||||
| Revenue | 8.68 M | ||||
| Gross Profit | 6.8 M | ||||
| EBITDA | (14.48 M) | ||||
| Net Income | (11.39 M) | ||||
| Cash And Equivalents | 11.49 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 262 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.12 X | ||||
| Book Value Per Share | 16.48 X | ||||
| Cash Flow From Operations | (16.96 M) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | 76.20 X | ||||
| Price To Earnings To Growth | (12.12) X | ||||
| Target Price | 1.0 | ||||
| Number Of Employees | 29 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 3.64 M | ||||
| Total Asset | 10.66 M | ||||
| Retained Earnings | (635.57 M) | ||||
| Working Capital | 6.52 M | ||||
| Net Asset | 10.66 M |
About ReShape Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ReShape Lifesciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ReShape Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ReShape Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.